<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05088707</url>
  </required_header>
  <id_info>
    <org_study_id>aswu/354/3/18</org_study_id>
    <nct_id>NCT05088707</nct_id>
  </id_info>
  <brief_title>Sublingual Versus Vaginal Misoprostol In Medical Treatment of Second Trimestric Missed Miscarriage</brief_title>
  <official_title>Sublingual Versus Vaginal Misoprostol In Medical Treatment of Second Trimestric Missed Miscarriage: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aswan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aswan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this work is to compare the effectiveness of vaginal versus sub-lingual&#xD;
      misoprostol for medical treatment of the second trimester missed miscarriage&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In women with second trimester-missed miscarriage, sublingual misoprostol may be as vaginal&#xD;
      misoprostol in the achievement of successful miscarriage so our aim was to compare the&#xD;
      effectiveness of vaginal versus sub-lingual misoprostol for medical treatment of the second&#xD;
      trimester missed miscarriage.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>an open-label randomized controlled study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>an open-label randomized controlled study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Completeness of abortion</measure>
    <time_frame>7 days</time_frame>
    <description>expulsion of Products of conception by visual inspection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Successful medical abortion</measure>
    <time_frame>7 days</time_frame>
    <description>cervical os is closed with endometrial thickness of less than 15 mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding pattern following treatment</measure>
    <time_frame>7 days</time_frame>
    <description>This will be assessed by hemoglobin(g/dl) and haematocrit level after the treatment , if the patients required blood transfusion and number of units transfused and number of days of bleeding</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Miscarriage</condition>
  <arm_group>
    <arm_group_label>sublingual misoprostol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive three doses of sublingual misoprostol every four hours. The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home.&#xD;
Two doses of misoprostol 800 mcg each (four tablets of 200 mcg per dose). Paracetamol, eight hourly, will be provided as an analgesic or antipyretic. A specimen bottle to collect the POC if passed out. Two pairs of disposable gloves. Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vaginal misoprostol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All patients will receive three doses of vaginal misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home.&#xD;
Paracetamol, eight hourly, will be provided as analgesic or antipyretic</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sublingual misoprostol</intervention_name>
    <description>All patients will receive three doses of sublingual misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of second dose will be given upon sending home.&#xD;
Two doses of misoprostol 800 mcg each (four tablets of 200 mcg per dose). Paracetamol, eight hourly, will be provided as analgesic or antipyretic. A specimen bottle to collect the POC if passed out. Two pairs of disposable gloves. Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception</description>
    <arm_group_label>sublingual misoprostol</arm_group_label>
    <other_name>experimental</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vaginal misoprostol</intervention_name>
    <description>All patients will receive three doses of vaginal misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home.&#xD;
Paracetamol, eight hourly, will be provided as analgesic or antipyretic</description>
    <arm_group_label>vaginal misoprostol</arm_group_label>
    <other_name>Active Comparator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All women above 18 years of age&#xD;
&#xD;
          -  between 13-26 weeks of gestation.&#xD;
&#xD;
          -  Pregnancy is confirmed by a pregnancy test or ultrasound scan.&#xD;
&#xD;
          -  missed abortion&#xD;
&#xD;
          -  Normal general and gynecological examination.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hemodynamically unstable.&#xD;
&#xD;
          -  Suspected sepsis with temperature 38 Â°C.&#xD;
&#xD;
          -  Concurrent medical illness e.g. hematological, cardiovascular, thromboembolism,&#xD;
&#xD;
          -  respiratory illnesses, recent liver disease, or pruritus of pregnancy.&#xD;
&#xD;
          -  Presence of intrauterine contraceptive device (IUCD).&#xD;
&#xD;
          -  Suspect or proven ectopic pregnancy.&#xD;
&#xD;
          -  -Failed medical or surgical evacuation before the presentation.&#xD;
&#xD;
          -  Known allergy to misoprostol.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>pregnant women with second missed abortion</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hany F Sallam, md</last_name>
    <phone>+201112505221</phone>
    <phone_ext>002</phone_ext>
    <email>hanysallam876@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>nahla w Shady, md</last_name>
    <phone>+201022336052</phone>
    <phone_ext>002</phone_ext>
    <email>hanygyne@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aswan University Hospital</name>
      <address>
        <city>Aswan</city>
        <zip>81528</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 10, 2021</study_first_submitted>
  <study_first_submitted_qc>October 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2021</study_first_posted>
  <last_update_submitted>October 10, 2021</last_update_submitted>
  <last_update_submitted_qc>October 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aswan University Hospital</investigator_affiliation>
    <investigator_full_name>hany farouk</investigator_full_name>
    <investigator_title>A Professor</investigator_title>
  </responsible_party>
  <keyword>miscarriage</keyword>
  <keyword>sublingual</keyword>
  <keyword>vaginal</keyword>
  <keyword>misoprostol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abortion, Spontaneous</mesh_term>
    <mesh_term>Abortion, Missed</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

